Department of Neural & Behavioral Sciences, Penn State University College of Medicine, 500 University Drive, Hershey, PA 17033-0850, USA.
Exp Biol Med (Maywood). 2010 Nov;235(11):1292-9. doi: 10.1258/ebm.2010.010203.
The imidazoquinolines are immune response modifiers that have potent antiviral and antitumor properties. The mechanism by which they exert their effects on cell replication has been investigated in vitro and is related to the upregulation of the opioid growth factor receptor (OGFr) and modulation of opioid growth factor (OGF; [Met(5)]-enkephalin). The OGF-OGFr axis regulates cell proliferative events through a cyclin-dependent kinase inhibitory pathway. The present study examined the mechanism whereby imiquimod repressed cell proliferation in vivo. Using a nude mouse model that has a compromised T-cell immune system, as well as C57BL/6 mice with an intact immune system, the effects of topical imiquimod (Aldara(®)) on DNA synthesis of basal epithelial cells in skin were examined. Imiquimod's effects on DNA synthesis were detected 24 h after application, and could be observed for one week after a single treatment. The magnitude of change in DNA synthesis following imiquimod was similar for one, three or six applications. Naloxone, an opioid antagonist, blocked the inhibitory effect of imiquimod. Imiquimod in combination with OGF or a low dose of naltrexone (LDN; known to upregulate the OGF-OGFr axis) had no greater inhibitory response on DNA synthesis than either OGF or LDN alone. Both OGF and OGFr were upregulated in basal epithelium after imiquimod treatment. Both nude and C57BL/6 mice exhibited the same repressive action of imiquimod on epithelial DNA synthesis. Imiquimod was neither an opioid agonist nor antagonist using nociceptive testing, and did not induce apoptosis or necrosis. Exposure to imiquimod was found to depress DNA synthesis in cells located in distant epithelium from day 3 and lasted until day 5. These results suggest that the target of imiquimod on DNA synthesis is dependent on an opioid receptor-mediated pathway, and infers that imiquimod is reliant on the OGF-OGFr axis for modulating cell proliferation.
咪唑并喹啉类化合物是免疫反应调节剂,具有强大的抗病毒和抗肿瘤特性。它们对细胞复制的作用机制已在体外进行了研究,与阿片样生长因子受体(OGFr)的上调和阿片样生长因子(OGF;[Met(5)]-脑啡肽)的调节有关。OGF-OGFr 轴通过细胞周期蛋白依赖性激酶抑制途径调节细胞增殖事件。本研究检查了咪喹莫特在体内抑制细胞增殖的机制。使用一种 T 细胞免疫系统受损的裸鼠模型以及一种免疫系统完整的 C57BL/6 小鼠,研究了局部咪喹莫特(Aldara(®))对皮肤基底上皮细胞 DNA 合成的影响。咪喹莫特对 DNA 合成的影响在应用后 24 小时即可检测到,并且在单次治疗后一周内仍可观察到。咪喹莫特对 DNA 合成的影响在一次、三次或六次应用后相似。阿片拮抗剂纳洛酮阻断了咪喹莫特的抑制作用。咪喹莫特与 OGF 或低剂量纳曲酮(LDN;已知上调 OGF-OGFr 轴)联合使用对 DNA 合成的抑制作用并不比 OGF 或 LDN 单独使用更强。咪喹莫特处理后,基底上皮中的 OGF 和 OGFr 均上调。裸鼠和 C57BL/6 小鼠均表现出咪喹莫特对上皮细胞 DNA 合成的相同抑制作用。咪喹莫特在疼痛测试中既不是阿片类激动剂也不是拮抗剂,也不会诱导细胞凋亡或坏死。发现接触咪喹莫特会导致远离上皮的细胞从第 3 天开始抑制 DNA 合成,并持续到第 5 天。这些结果表明,咪喹莫特对 DNA 合成的作用靶点依赖于阿片受体介导的途径,并推断咪喹莫特依赖于 OGF-OGFr 轴来调节细胞增殖。